Date: Sunday, June 2, 2019
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall C & D
*Purpose: Refractory ascites at perioperative period in liver transplantation (LT) is associated with the increased morbidity and mortality. The aim of this study is to investigate the efficacy and safety of novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for the treatment of refractory ascites in LT candidates.
*Methods: Total 44 times of KM-CART were performed for the 8 LT candidates at our hospital between September 2017 and November 2018. We investigated the safety and effectiveness of KM-CART regarding the processed ascites, the adverse events, the lab data, and the use of blood products.
*Results: By using KM-CART, 11.3 L (2.6 L – 26.1 L) of ascites were filtrated and concentrated to 0.5 L (0.1 L – 1.6 L) in 59.5 min (8 min – 187 min). Final products contained 22.1 g (2.5 g – 65.5 g) of albumin and 17.7 g (1.5 g – 61.8 g) of globulin. No endotoxin contamination was detected in the ascites. Although the incidence of adverse event was 36.4% (including fever, hypotension, bleeding, leg cramps, and nausea), all of these could be treated conservatively. Body weight, oral intake was significantly improved after KM-CART. Furthermore, the use of fresh frozen plasma for the LT recipients with KM-CART was significantly lower than that for patients without KM-CART. In addition, no patients lost their opportunity for LT because of adverse events by KM-CART.
*Conclusions: KM-CART was effective and safe procedure for the treatment of refractory ascites in LT candidates. These results would provide the foundation for further large-scale prospective studies.
To cite this abstract in AMA style:Sato K, Ohira M, Imaoka Y, Hashinoto S, Tahara H, Ide K, Kobayashi T, Tanaka Y, Ohdan H. Novel Cell-Free and Concentrated Ascites Reinfusion Therapy for Management of Refractory Ascites in Liver Transplant Candidates [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/novel-cell-free-and-concentrated-ascites-reinfusion-therapy-for-management-of-refractory-ascites-in-liver-transplant-candidates/. Accessed September 29, 2020.
« Back to 2019 American Transplant Congress